ESC 365 - Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

ESC Professional Premium Access

Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials

Session: Antithrombotic and anticoagulant therapy

Topic: Pharmacotherapy

Speaker: Doctor S. Delgado (Taguig, PH)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Samantha Delgado

Saint Lukes Medical Center Global City, Taguig (Philippines)

0 follower

8 more presentations in this session

Associations between DAPT score and long-term mortality post PCI

Speaker: Doctor M. Tan (Melbourne, AU)

Ticagrelor or prasugrel in patients with acute coronary syndrome and high bleeding risk

Speaker: Doctor S. Lahu (Munich, DE)

Intracoronary thrombolysis facilitated primary percutaneous coronary intervention in ST-segment elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials

Speaker: Doctor S. Alexiou (Thessaloniki, GR)

Abbreviated dual antiplatelet therapy after PCI in patients at high bleeding risk: a collaborative meta-analysis of randomized trials

Speaker: Doctor F. Costa (Messina, IT)

Perioperative risk and benefit of antiplatelet therapy in patients undergoing non-cardiac surgery within 1 year after percutaneous coronary intervention with second-generation drug-eluting stents.

Speaker: Doctor S. Lee (Seoul, KR)

Access the full session

Antithrombotic and anticoagulant therapy

Speakers: Doctor S. Delgado, Doctor M. Tan, Doctor S. Lahu, Doctor S. Alexiou, Doctor F. Costa...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources